Rare EGFR exon 20 S768I mutation predicts resistance to targeted therapy: A report of two cases

Journal of Thoracic Oncology

Volumn 9, Issue 10, 2014, Pages e75-

  Pallan, Lalit ^a   Taniere, Phillipe ^b   Koh, Pek ^a  

^a NEW CROSS HOSPITAL   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; ISOLEUCINE; NAVELBINE; PEMETREXED; SERINE; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ADENOCARCINOMA; ADULT; AGED; AMINO ACID SUBSTITUTION; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CASE REPORT; CODON; COMPUTER ASSISTED TOMOGRAPHY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EXERCISE TOLERANCE; EXON; FEMALE; HOSPITAL ADMISSION; HUMAN; INCIDENTAL FINDING; LETTER; LIVER METASTASIS; LUNG EMBOLISM; LYMPHADENOPATHY; MALE; MEDIASTINUM LYMPHADENOPATHY; MISSENSE MUTATION; MULTIPLE CYCLE TREATMENT; PNEUMONIA; POORLY DIFFERENTIATED ADENOCARCINOMA; PRIORITY JOURNAL; RETROPERITONEAL LYMPHADENOPATHY; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MUTATION;

AGED; DRUG RESISTANCE, NEOPLASM; EXONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84925785782     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000308     Document Type: Letter

References (5)

1. Yatabe Y, Pao W, Jett JR. Encouragement to submit data of clinical response to EGFR-TKIs in patients with uncommon EGFR mutations. J Thorac Oncol 2012;7:775-776.
2. Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004;10:8195-8203.
3. Chen YR, Fu YN, Lin CH, et al. Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. Oncogene 2006;25:1205-1215.
4. Masago K, Fujita S, Irisa K, et al. Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I). Jpn J Clin Oncol 2010;40:1105-1109.
5. Weber B, Hager H, Sorensen BS, et al. EGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in Danish patients with non-small cell lung cancer. Lung Cancer 2014;83:224-230.